Background and Objectives: Although herbal medicine-based obesity treatment programs are used in obesity management, empirical research on patient acceptability remains limited. This study examined acceptability of a Korean medicine-based obesity treatment program (KM-OBP) among patients who achieved predefined weight-loss targets in routine clinical care. Materials and Methods: Medical records and satisfaction survey data routinely collected during clinical practice at a single Korean medicine clinic were retrospectively analyzed. Patients had baseline body mass index (BMI) ≥ 30 kg/m2 and achieved both ≥10% weight loss and BMI ≤ 23 kg/m2 during follow-up. BMI trajectories and adverse-event occurrence were summarized descriptively. Satisfaction ratings were reported on a 5-point Likert scale, and free-text responses were retrospectively analyzed using the Theoretical Framework of Acceptability. Results: Of 3798 patients with a baseline BMI ≥ 30 kg/m2 and at least two BMI measurements, 37 (0.97%) met the predefined targets; 16 completed the satisfaction survey. Mean BMI change from the first to last measurement was −8.9 kg/m2, and median change was −8.8 kg/m2 (interquartile range, −9.6 to −7.7). Common documented adverse events were constipation, nausea, and dizziness. Satisfaction ratings were descriptively high for the overall program, perceived helpfulness for obesity treatment, and herbal medicine. Among the 16 survey respondents, perceived weight-loss benefits, program structure, safety, and health improvement were described as facilitators of acceptability, whereas post-treatment weight regain, dietary burden, and financial concerns were described as barriers. Conclusions: The findings characterize satisfaction and reported acceptability experiences among survey respondents within a highly selected target-achieving cohort. Interpretation is limited by outcome-based selection, potential non-response bias, the small survey sample, and the single-center design.
Background/Objectives: Subjective memory complaints (SMCs) represent an early window for cognitive intervention; however, no approved pharmacological treatment exists at this stage. Gastrodia elata is a traditional medicinal plant, and preclinical studies suggest that it may influence synaptic plasticity, neurotrophic signaling, and neuroinflammatory pathways involved in memory; however, human evidence remains limited. Methods: This study was a randomized, participant- and assessor-blinded, placebo-controlled clinical trial in which the Clinical Research Coordinator, statistician, physician, and participants remained unaware of group assignment throughout the study period. Eighty adults with normal objective cognitive function and subjective memory complaints were randomized; 76 participants were included in the full analysis set (36 G. elata, 40 placebo) and all 80 in the safety set. Results: The prespecified primary outcome showed a small between-group difference in MoCA-K total score change: G. elata 0.72 ± 1.34 vs. placebo 0.13 ± 1.07 (between-group p = 0.034). Exploratory secondary analyses showed significant differences in MoCA-K delayed recall, K-MMSE total, K-MMSE memory recall and BDNF, whereas Digit Span and IL-6 did not differ significantly between groups. No serious adverse events occurred. The trial was retrospectively registered in CRIS (KCT0011966) on 12 May 2026. Conclusions: These findings provide preliminary evidence that G. elata supplementation may support selected cognitive outcomes in adults with SMCs, although the clinical relevance requires confirmation in larger, prospectively registered trials. Further studies incorporating neuroimaging and prespecified biomarker analyses are warranted to determine whether the observed cognitive findings are accompanied by objective changes in brain function or circulating biomarkers.